GLP-1

U.S. stock futures are flat as investors digest tariff uncertainties following a Supreme Court ruling and President Trump’s new duties. In AI, Meta inked a major deal with AMD for GPUs, diversifying its supply chain after a similar Nvidia agreement. Eli Lilly launched a more convenient pen for its obesity drug, Zepbound, as competition in the GLP-1 market intensifies. Meanwhile, violence in Mexico following a cartel leader’s death disrupts trade and travel.

DocGo’s virtual care division, SteadyMD, is significantly expanding its clinical staff by up to 50% to meet surging demand for GLP-1 weight loss program support from major clients. This strategic hiring initiative aims to scale operations, ensuring high-quality, compliant virtual care and accommodating growing patient needs nationwide. The expansion underscores SteadyMD’s commitment to being a foundational platform for modern healthcare delivery.

words.Structure Therapeutics (NASDAQ: GPCR) will announce topline results from its ACCESS trial of alenigilprion, an oral GLP‑1 receptor agonist for obesity, before market open on Monday, Dec 8 2025. Management will discuss the data in a conference call and webcast at 8:30 a.m. ET, with a replay posted two hours later and available for 90 days. The release follows previous catalyst‑driven updates and aligns with the company’s cash‑rich outlook and ongoing oral‑therapy strategy.